Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.040423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Anran Xin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of …. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Like 1 Protein, Immunoglobulin Light-chain Amyloidosis, Cardiomyopathies. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The prognostic significance of dynamic changes in soluble suppression of tumorigenicity‐2 (sST2) in patients with light chain cardiac amyloidosis (AL‐CA) remains unclear. We aimed to evaluate the prognostic significance of both baseline sST2 and 30‐day changes (ΔsST2) in patients with light chain cardiac amyloidosis.
Methods
Patients diagnosed with light chain cardiac amyloidosis in Heart Failure Center, Fuwai Hospital (October 2015–May 2024) were enrolled in the entire cohort, with baseline sST2 measured. A prospective subcohort (October 2023–May 2024) also underwent 30‐day repeat sST2 measurement. ΔsST2 was defined as the sST2 level at 30 days minus baseline sST2. The primary outcome was all‐cause mortality. Prognostic value of both baseline and ΔsST2 was assessed using Kaplan–Meier and Cox models. The relationships between variables and primary outcome were examined with restricted cubic splines.
Results
In the entire cohort with 172 patients included (mean age 60.35±10.21 years; 40.1% women; median follow‐up 310 days), higher baseline sST2 levels (>35 ng/mL) were independently associated with increased all‐cause mortality risk (adjusted hazard ratio [HR], 1.82 [95% CI, 1.13–2.91], P 18 ng/mL) was also an independent indicator of worse prognosis (adjusted HR, 9.87 [95% CI, 1.90–51.11], P 35 ng/mL) and short‐term increases in sST2 predict poor prognosis in patients with light chain cardiac amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing…
- Key Laboratory of Clinical Research for Cardiovascular Medications National Health Committee Beijing China.
ORCID-Profile: Ping Zhou, Xuemei Zhao, Jian Zhang, Yuhui Zhang
Zitieren
APA
Xin, A., Li, X., Huang, Y., Zhou, Q., Zhuang, X., Liu, H., Zhou, P., Wang, J., Zhao, X., Zhang, J., & Zhang, Y. (2025). Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040423
Vancouver
Xin A, Li X, Huang Y, Zhou Q, Zhuang X, Liu H, et al. Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040423
BibTeX
@article{Xin2025,
author = {Xin, Anran and Li, Xinqing and Huang, Yan and Zhou, Qiong and Zhuang, Xiaofeng and Liu, Huihui and Zhou, Ping and Wang, Jinxi and Zhao, Xuemei and Zhang, Jian and Zhang, Yuhui},
title = {Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.040423}
}
EUVIMED